Immunotherapy for Pemphigus: Present and Future
Pemphigus is a chronic and severe autoimmune bullous disease caused by autoantibodies targeting adhesion molecules between keratinocytes. It requires 2–3 years on average to manage the disease. To date, although Rituximab combined with short-term systemic glucocorticoids was accepted as first-line t...
Main Authors: | Huijie Yuan, Meng Pan, Hongxiang Chen, Xuming Mao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.901239/full |
Similar Items
-
Major autoantibodies in pemphigus: detection and clinical significance
by: WANG Qijun, ZHU Haiqin, PAN Meng
Published: (2022-10-01) -
An Updated Review of Pemphigus Diseases
by: Ali M. Malik, et al.
Published: (2021-10-01) -
Localized pemphigus foliaceus: Diverse presentations, treatment, and review of the literature
by: Anuj Kunadia, et al.
Published: (2023-01-01) -
Advanced diffuse hepatic angiosarcoma treated successfully with TACE and targeted immunotherapy: A case report
by: Yucheng Lin, et al.
Published: (2023-04-01) -
Case report: Mounded and refractory keratoses (MARK), a novel presentation of pemphigus vulgaris
by: Stephanie T. Le, et al.
Published: (2023-01-01)